Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
894.5 USD | +0.06% | -1.31% | +1.65% |
Apr. 17 | UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating | MT |
Apr. 17 | The market is pinning its hopes on earnings reports |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.65% | 96.07B | |
-3.17% | 102B | |
-1.80% | 21.66B | |
-17.78% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.01% | 13.79B | |
+0.02% | 13.33B | |
+18.90% | 10.94B | |
-22.89% | 8.57B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals : Antibody Cocktail Gets Full Approval in Japan as Treatment for Mild to Moderate COVID-19